The 15 Hemophilia Treatment Centers in Mid-Atlantic Region III report statistics regarding their patient population to the Core Center annually. This information is used for reporting to our federal grant agency, the Maternal and Child Health Bureau, and is also used by the Core Center for monitoring, budget apportionments and program planning.
Active patients by age, race and gender
In 2017, HTCs in the Mid-Atlantic Region III reported 3,495 total patients.
- 31 percent are female
- 79 percent are Caucasian
- 15 percent are African-American
- 10 percent are Hispanic
Active patients by diagnosis
Bleeding disorders
- Hemophilia A or B: 1941 patients (56 percent)
- Von Willebrand disease: 1066 patient (31 percent); 65 percent of female
Thrombosis patients
- 799 patients were reported in our region from nine of our HTCs; 57 percent of these patients are female.
Other factor deficiencies
- 196 patients with a deficiency in factor I, II, V, VII, X, XI or XIII. These patients represent 6 percent of the patients in the region.
Evaluations
- 1,188 comprehensive evaluations were conducted at HTCs in 2017.
Home therapy
- 830 patients with hemophila (55 percent) are on home therapy.
Primary care physicians (PCPs)
- 1,295 patients in Mid-Atlantic Region III had an identified PCP.
Year-to-year changes
- 3.4 percent increase in patients in the Region from 2015 to 2017
- 2.5 percent decrease in patients in the Region from 2013 to 2015